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INTRODUCTION
Oral anticoagulation therapy (OAT) 
substantially reduces thromboembolic 
events with no increase in major 
haemorrhagic events.1–5 However, uptake 
is still affected by the need to maintain 
the international normalised ratio (INR) in 
a narrow range, which requires frequent 
testing and dose adjustment. Reliable and 
accurate point-of-care devices enable 
patients to test their INR in their own 
setting. They can either self-monitor their 
INR and have their oral anticoagulation 
dosage managed by a healthcare provider 
or they can self-manage and adjust their 
own dosage. 
Patients have been found to vary 
considerably in their ability to self-monitor 
and self-manage. Results of randomised 
controlled trials (RCTs) show that only 38% 
(range 12–59%) of those initially identified 
as potentially eligible for self-monitoring 
of OAT actually participated in the trials; 
in addition, only 78% assigned to the 
intervention continued self-monitoring until 
the end of the trial.6
Current guidelines recommend self-
monitoring or self-management for 
patients who have long-term indications, 
a recognised target INR, and have 
received appropriate training by a health 
professional.2,7 The outcomes of the trials 
for those that participate fully have been 
positive for both self-monitoring and self-
managing OAT,3 but it is not known whether 
these results translate into routine practice. 
This study aimed to: 
• prospectively estimate the current levels 
of control and adverse events in patients 
self-monitoring OAT in the UK;
• explore the factors that predict successful 
self-monitoring of INR;
• ascertain whether the success of INR 
self-monitoring and level of side effects 
reported in RCTs of self-monitoring 
INR are translated to a non-selected 
population; and 
• estimate the adequacy of existing training 
and quality-assurance arrangements. 
METHOD
Study population and recruitment
The study population consisted of all people 
who purchased an INR self-monitoring 
device from the main distributor in the UK. 
During the study period, this distributor had 
99.9% of the market share. 
All people aged ≥18 years, who were 
able to give informed consent, comprehend 
English sufficiently well to be interviewed, 
and registered with a UK GP were 
eligible to take part. Recruitment lasted 
from February 2009 until August 2011. 
Originally, only those who were new to self-
monitoring — defined as self-monitoring 
for ≤3 months — were recruited. However, 
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due to low numbers, recruitment was 
broadened to include people who had been 
self-monitoring for some time and were 
purchasing replacement devices.
Sample size
As the primary aim of the study was to 
obtain an adequate estimate of the rate 
of successful self-monitoring, the sample 
size calculation was based on a certain 
precision around this estimate (equal to 
1.96 standard errors, or one side of a 95% 
confidence interval [CI]). The worse-case 
scenario in terms of precision, given a rate 
of 50% (maximum variance) and a 20% 
attrition, would require 300 participants 
to achieve a precision of ±6% around the 
estimate (for example, 95% CI = 44 to 56). 
A rate of 35% (or 65%) based on the same 
sample would give a precision of ±5.4%. 
Rates of <35% (or >65%) would give better 
precision levels. This sample also allows 
for the identification of predictive variables 
with odds of greater than approximately 
2.5 — for example, an odds ratio [OR] of 2.3 
for an event of 70% in the successful group, 
versus 50% in the unsuccessful group — 
with similar confidence.
Baseline telephone interviews and 
questionnaires
Consenting participants were sent a postal 
questionnaire and telephoned to complete 
a baseline interview. Details requested 
covered: 
• basic demographics;
• anticoagulation history;
• self-monitoring training;
• support;
• adverse events;
• quality assurance;
• comorbidity;
• medications;
• attitudes towards self-monitoring of INR;
• confidence about self-monitoring INR; 
and 
• psychosocial measures. 
The psychosocial measures comprised the 
EQ-5D,8 Conscientiousness scale,9 Morisky 
Adherence to Medication Scale,10 National 
Institute of Health and Care Excellence 
(NICE) Depression Screening Tool,11 State-
Trait Anxiety Inventory,12 Hospital Anxiety 
and Depression Scale,13 Brief Illness 
Perception Questionnaire,14 an adapted 
Treatment Self-Regulation Questionnaire 
including perceived  competence/self-
efficacy scale and Health Care Climate 
Questionnaire,15 (based on the theory of self-
determination)16 and the Theory of Planned 
Behaviour Questionnaire.17 
Interview schedule
Face-to-face interviews were conducted 
with a small number of participants. 
Interviews were semi-structured with open-
ended questions to elicit new information; 
they were recorded using digital audio 
equipment and transcribed. Questions 
explored the: 
• experiences of self-monitoring, focusing 
on the barriers and facilitators;
• reasons for not starting, or not continuing, 
self-monitoring; 
• training received; and 
• quality assurance.
Follow-up data collection
Participants were contacted by telephone 
at 3, 6, and 12 months to ascertain whether 
they were still self-monitoring; a brief 
questionnaire explored their experiences of 
doing so. At 12 months, participants were 
also sent a validated questionnaire to assess 
their oral anticoagulation knowledge.18 
During follow-up, they recorded their INR 
data in a log book and posted it to the study 
coordinator every 3 months. Clinical data for 
participants for the 12-month study period 
were ascertained from GP medical records. 
Two GPs independently classified the 
reported adverse events using the bleeding 
severity index;19 differences were resolved 
by discussion. 
How this fits in
Oral anticoagulation therapy (OAT) greatly 
reduces thromboembolic events without 
increasing major haemorrhagic events. 
The outcomes of a number of trials have 
been positive for both self-monitoring 
and self-managing oral anticoagulation, 
but it is not known whether these results 
translate into routine practice. This study 
shows that, even without much training, 
individuals on OAT can self-monitor, and 
even self-manage, their international 
normalised ratio (INR) with positive results 
outside of trial settings. Such patients 
could be offered self-monitoring and self-
management of their OAT with suitable 
healthcare support. However, it should be 
noted that participants in this study were 
highly educated so caution should be taken 
with regard to generalising the findings to 
the broader population. 
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Data analysis
Statistical analyses were performed 
using SPSS (version 20). Comparisons of 
descriptive data were conducted using c2 
tests for categorical variables and binary 
logistic regression for continuous variables. 
The proportion of participants continuing 
to self-monitor over time was ascertained 
from the interview data, while the proportion 
of time in therapeutic range (TTR) was 
calculated using the INR data. Percentage 
TTR (%TTR) was calculated using Rosendaal 
et al’s method20 in Stata (version 11). 
Successful self-monitoring was defined 
as the proportion of participants:
• continuing to self-monitor for 12 months;
• not experiencing adverse events over the 
12 months; and 
• achieving >80%TTR. 
In the calculation of TTR, the participant’s 
reported target range was used for 
analyses; participant-reported INR tests 
conducted by health professionals were 
excluded. Duplicate tests carried out on 
the same day were averaged. The start 
date was taken as the date of the baseline 
interview; the end date was 365 days later. 
Participant INR data was excluded if the 
submitted test results spanned <90 days 
in total during the study period. TTR was 
not interpolated for the missing periods. 
Data with a reported gap between tests of 
>12 weeks was treated as intermittent. 
Forward stepwise logistic regression was 
used to establish potential predictors of 
successful self-monitoring. Only baseline 
characteristics were included in the model; 
the addition of whether a participant had 
experienced a surgical procedure during 
the 12 months was excepted as this was 
likely to reduce TTR. Age, sex, condition 
requiring oral anticoagulation, duration of 
self-monitoring, surgical procedure during 
follow-up, and previous oral anticoagulation 
complications were all entered into a model 
before the addition of baseline variables 
with a univariate OR P-value of <0.10. 
RESULTS
Of the individuals approached to participate 
in the study, 299 were eligible, completed 
the baselines questionnaires, and were 
recruited. Of these, three participants did 
not go on to begin self-monitoring (two due 
to lack of support from their healthcare 
provider and one for unknown reasons). 
Of the remaining 296 (from 290 general 
practices), 15 were lost to follow-up, seven 
stopped using OAT, and seven stopped 
self-monitoring; this gave a total of 267 
(90.2%) who were still self-monitoring at 
12 months (Figure 1). Of those who stopped 
self-monitoring, four did so due to lack 
of healthcare provider support, two were 
unable to use the monitor reliably, and one 
was for unknown reasons.
Baseline characteristics 
The baseline characteristics of the cohort 
are presented in Table 1. In total, 51.2% 
were new to self-monitoring. The median 
target INR was 2.5 (interquartile range [IQR] 
2.5–3.2). This varied by condition as follows:
• atrial fibrillation: median INR target of 2.5 
(IQR 2.5–2.5);
• mechanical heart valve: median INR 
target of 3.0 (IQR 3.0–3.5);
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Self-monitoring at 12 months: n = 267
Self-monitoring at 6 months: n = 278
Self-monitoring at 3 months: n = 284
Began self-monitoring: n = 296
Baseline assessment completed: n = 299
Consent forms received: n = 373
Withdrew from cohort: n = 6
Ineligible: n = 44
Could not give informed consent: n = 1
Lived outside of the UK full time: n = 1
Not new to self-monitoring (prior to study
amendment): n = 42
Baseline assessment not completed: n = 24
Questionnaire not returned: n = 23
Could not be contacted for telephone
interview: n = 1
Did not begin self-monitoring: n = 3
Could not be contacted for 3-month assessment: n = 4
No longer required oral anticoagulation therapy: n = 3
Stopped self-monitoring: n = 5 
Could not be contacted for 6-month assessment: n = 4 
No longer required oral anticoagulation therapy: n = 1
Stopped self-monitoring: n = 1 
Could not be contacted for 12-month assessment: n = 7
No longer required oral anticoagulation therapy: n = 3
Stopped self-monitoring: n = 1
Figure 1. Flow chart of recruitment process.
• thrombosis: median INR target of 2.5 
(IQR 2.5–3.0); and 
• antiphospholipid syndrome: median INR 
target of 3.5 (IQR 2.5–3.8).
Just under half of participants self-
monitored but received assistance with 
dose adjustment (133/296, 44.9%), while 
others self-managed and adjusted their 
own medication (116/296, 39.2%). A smaller 
number (47/296, 15.9%) did a mixture of 
both. Those new to self-monitoring were 
significantly less likely to be self-managing 
(25.7%, P<0.001) than those who had been 
self-monitoring for a longer period of time 
(53.5%). 
Table 2 details participants’ psychosocial 
characteristics. More than half had 
problems in one or more dimensions of the 
EQ-5D (153/292, 52.4%), with the largest 
percentage being for those experiencing 
pain (122/296, 41.2%). Those who had been 
self-monitoring for longer had higher self-
efficacy scores (P = 0.003), higher social 
pressure scores (P = 0.030), felt more in 
control of their illness (P = 0.014), and 
thought that their treatment controlled 
their illness more (P = 0.020). According 
to the NICE depression screening tool just 
over one-quarter (26.9%) of the participants 
were depressed, however, according to 
their HADS scores they were no more 
depressed and were slightly less anxious 
than the general population (Appendix 1). 
Training details
Nearly all participants (92.9%) made use of 
the information book and/or DVD that came 
with the monitor. However, only 45.9% of 
participants had received in-person training 
with a median duration of 35 minutes. Only 
six of 39 (15.4%) of those new to self-
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Table 1. Baseline characteristics
Baseline characteristic n Total cohorta n New to self-monitoringb n Ongoing self-monitoringc P-valued
Demographic 
 Age, median (IQR) 295 61.0 (50.0–68.0) 152 59.0 (49.0–66.0) 143 63.0 (52.0–69.0) 0.031
 Male, n (%) 296 163 (55.1) 152 88 (57.9) 144 75 (52.1) 0.315
 White ethnicity, n (%) 294 293 (99.7) 150 149 (99.3) 144 144 (100.0) 1.000
Highest educational qualification attained 294  152  143  0.582
 No qualification, n (%)  16 (5.4)  10 (6.6)  6 (4.2) 
 O-Level or GCSE, n (%)  22 (7.5)  10 (6.6)  12 (8.4)
 A-Level, n (%)  13 (4.4)  8 (5.3)  5 (3.5)
 Professional qualification, n (%)  91 (31.0)  42 (27.8)  49 (34.3)
 University degree, n (%)  152 (51.7)  81 (53.6)  71 (49.7)
Condition requiring anticoagulation 296  152  144  0.403
 Antiphospholipid syndrome, n (%)  25 (8.4)  13 (8.6)  12 (8.3) 
 Atrial fibrillation, n (%)  68 (23.0)  40 (26.3)  28 (19.4)
 Mechanical heart valve, n (%)  97 (32.8)  44 (28.9)  53 (36.8)
 Thrombosis, n (%)  106 (35.8)  55 (36.2)  51 (35.4)
Oral anticoagulation history
 Target INR, median (IQR) 296 2.5 (2.5–3.2) 152 2.5 (2.5–3.0) 144 3.0 (2.5–3.3) 0.088
 Duration of OAT, months, median (IQR) 295 62.0 (14.0–137.0) 151 21.0 (7.0–74.0) 144 107.0 (56.3–162.5) <0.001
 Previous OAT complication, n (%) 295 101 (34.2) 152 48 (31.6) 143 53 (37.1) 0.321
 Taking OAT other than warfarin, n (%) 296 10 (3.4) 152 4 (2.6) 144 6 (4.2) 0.469
Characteristics of self-monitoring
 Duration, months, median (IQR)  295 2.0 (1.0–65.0) 151 1.0 (0.0–1.0) 144 65.0 (8.8–94.5) <0.001
 Received in-person self-monitoring training, n (%) 296 136 (45.9) 152 69 (45.4) 144 67 (46.5) 0.845
 Duration of in-person training for those that 129 35.0 (20.0–60.0) 66 30.0 (20.0–60.0) 63 45.0 (20.0–80.0) 0.010 
   received it in minutes, median (IQR)
Other medications
 Total medications, median (IQR) 296 3.0 (1.0–5.0) 152 3.0 (1.0–5.0) 144 3.0 (1.0–6.0) 0.213
 Polypharmacy (total >3), n (%) 296 129 (43.6) 152 62 (40.8) 144 67 (46.5) 0.320
 Taking medication that affects anticoagulation, n (%) 296 167 (56.4) 152 83 (54.6) 144 84 (58.3) 0.580 
Oral anticoagulation dose management 296  152  144  <0.001
 Self-testing, n (%)  133 (44.9)  79 (52.0)  54 (37.5) 
 Mixed, n (%)  47 (15.9)  34 (22.4)  13 (9.0) 
 Self-managing, n (%)  116 (39.2)  39 (25.7)  77 (53.5) 
an = 296. bn = 152. cn = 144. dP-values calculated using c 2 for categorical variables and binary logistic regression for continuous variables. GCSE = General Certificate of 
Secondary Education. IQR = interquartile range. OAT = oral anticoagulation therapy.
monitoring who were also self-managing 
had received any in-person training at 
baseline. Those new to self-monitoring who 
were self-testing or doing a mixture were 
more likely to receive training (59.5% and 
47.1% respectively). The majority of this 
training took place in an outpatient hospital 
setting (62.5%), followed by primary care 
(36.8%); the remainder received training 
in both settings. Throughout the study 
period, 36/267 (13.5%) participants received 
additional training.
Knowledge of oral anticoagulation
At 12 months, the participants had a high 
level of knowledge about OAT on the 
20-item questionnaire (median score 18.0, 
IQR 16.0–19.0). There was no difference 
between those new to self-monitoring 
and those ongoing with self-monitoring. 
There was also no association between 
knowledge score and receiving in-person 
training (P = 0.658) or >80%TTR (P = 0.370). 
Areas where knowledge was lower were: 
• diet and supplements;
• additional medication;
• testing frequency; and 
• when to seek medical attention.
Adverse events
Reports on adverse events were obtained 
from the GPs of 255 (86.1%) participants. 
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Table 2. Psychosocial factors
Psychosocial factors n Total cohorta n New to self-monitoringb n Ongoing self-monitoringc P-valued
EQ-5D
 Total score, median (IQR) 292 6.0 (5.0–8.0) 150 6.0 (5.0–8.0) 142 5.0 (5.0–7.3) 0.401
 Problem in any dimension, n (%) 292 153 (52.4) 150 87 (58.0) 142 66 (46.5) 0.049
 Mobility problem, n (%) 296 88 (29.7) 152 47 (30.9) 144 41 (28.5) 0.645
 Self-care problem, n (%) 296 31 (10.5) 152 15 (9.9) 144 16 (11.1) 0.727
 Problem with usual activities, n (%) 295 92 (31.2) 152 53 (34.9) 143 39 (27.3) 0.160
 Pain, n (%) 296 122 (41.2) 152 67 (44.1) 144 55 (38.2) 0.304
 Anxiety problem, n (%) 293 69 (23.5) 150 41 (27.3) 143 28 (19.6) 0.119
 Visual scale, median (IQR) 292 80.0 (65.0–90.0) 150 78 (60.0–90.0) 142 80.0 (69.8–90.0) 0.156
Depression and anxiety
 Depressed NICE screening tool, n (%) 294 79 (26.9) 150 47 (31.3) 144 32 (22.2) 0.079
 Depressed assessed via HADS, n (%) 295 46 (15.6) 152 26 (17.1) 143 20 (14.0) 0.461
 Anxious assessed via HADS, n (%) 295 70 (23.7) 152 34 (22.4) 143 36 (25.2) 0.571
 STAI trait anxiety score, median (IQR) 295 33.0 (28.0–44.0) 151 32.0 (27.0–44.0) 144 33.0 (29.0–44.0) 0.878
Self-determination theory
 Autonomy score, median (IQR) 295 4.8 (3.8–5.5) 151 4.8 (4.0–5.5) 144 4.8 (3.8–5.5) 0.415
 Control score, median (IQR) 295 1.0 (1.0–2.5) 151 1.3 (1.0–2.3) 144 1.0 (1.0–2.5) 0.680
 Relative autonomy index, median (IQR) 295 3.0 (1.8–4.0) 151 3.0 (2.0–4.3) 144 2.9 (1.5–3.8) 0.307
 Self-efficacy maximum marks, n (%) 296 250 (84.5) 152 119 (78.3) 144 131 (91.0) 0.003
 Health care climate score, median (IQR)  294 34.0 (24.0–41.0) 150 33.0 (20.0–41.0) 144 34.0 (27.0–42.0) 0.185
Theory of planned behaviour
 Attitude score, median (IQR) 296 6.0 (5.5–7.0) 152 6.0 (5.5–7.0) 144 6.0 (5.5–7.0) 0.309
 Social pressure score, median (IQR) 296 5.0 (4.0–7.0) 152 4.5 (4.0–6.4) 144 5.5 (4.0–7.0) 0.030
 Control score, median (IQR) 296 7.0 (6.5–7.0) 152 7.0 (6.5–7.0) 144 7.0 (7.0–7.0) 0.099
 Intention score, median (IQR) 296 7.0 (7.0–7.0) 152 7.0 (7.0–7.0) 144 7.0 (7.0–7.0) 0.526
Illness perception
 Consequences, median (IQR) 295 3.0 (2.0–7.0) 152 4.5 (2.0–7.0) 143 3.0 (1.0–6.0) 0.600
 Timeline, median (IQR) 295 10.0 (10.0–10.0) 152 10.0 (10.0–10.0) 143 10.0 (10.0–10.0) 0.002
 Personal control, median (IQR) 294 6.0 (3.0–8.0) 152 6.0 (3.0–8.0) 142 7.0 (4.0–8.0) 0.014
 Treatment control, median (IQR) 295 9.0 (8.0–10.0) 152 9.0 (7.0–10.0) 143 9.0 (8.0–10.0) 0.020
 Identity, median (IQR) 295 3.0 (1.0–6.0) 152 3.0 (1.0–6.0) 143 2.0 (1.0–6.0) 0.150
 Concern, median (IQR) 295 5.0 (2.0–8.0) 152 6.0 (3.0–8.0) 143 4.0 (2.0–7.0) 0.008
 Understanding, median (IQR) 295 9.0 (8.0–10.0) 152 9.0 (8.0–10.0) 143 10.0 (8.0–10.0) 0.719
 Emotional response, median (IQR) 294 3.0 (1.0–6.0) 151 4.0 (1.0–7.0) 143 2.0 (0.0–5.0) 0.001
Other
 Requiring social assistance, n (%) 294 83 (28.2) 150 44 (29.3) 144 39 (27.1) 0.668
 Conscientiousness, median (IQR) 282 41.0 (36.0–45.0) 143 42.0 (36.0–46.0) 139 41.0 (36.0–45.0) 0.878
 Perfect medication adherence score, n (%) 288 176 (61.1) 149 94 (63.1) 139 82 (59.0) 0.856
an = 296. bn = 152. cn = 144. dP-values calculated using c 2 for categorical variables and binary logistic regression for continuous variables. HADS = Hospital Anxiety and 
Depression Scale. IQR = interquartile range. NICE = National Institute for Health and Care Excellence. STAI = State-Trait Anxiety Inventory.
Six (2.4%) participants experienced 
a serious adverse event — two deaths 
(one cause not reported, one from bowel 
cancer), two major bleeds, one thrombosis, 
and one transient ischaemic attack (TIA) 
— two experienced a minor bleed, and 18 
experienced bleeds that were adjudicated 
to be less minor, as defined by the bleeding 
severity index. There were no significant 
differences in baseline characteristics 
between those with (n = 255) and without 
(n = 41) GP reports. 
Twenty-eight participants self-
reported adverse events, comprising 
serious adverse events (one TIA, three 
major bleeds), minor bleed (n = 4), and 
sub-minor bleed (n = 20). Of these, one 
serious adverse event (major bleed while 
participant was abroad), three minor 
bleeds, and 15 sub-minor bleeds were not 
reported by the participant’s GP. There 
were no significant differences between 
those new to, and those ongoing with, self-
monitoring in terms of adverse events. 
There were also no differences between 
those who were self-managing and those 
who were self-testing.
Frequency of testing
Participants reported a median of 10.9 days 
between tests (IQR 7.2–17.4). Those who 
had been self-monitoring for longer tested 
marginally more frequently (median 11.4 
versus 10.5 days). Frequency of testing 
varied by condition: 
• antiphospholipid syndrome: tested most 
frequently, median days between tests 
8.0 (IQR 4.4–10.8);
• mechanical heart valve: median days 
between tests 10.8 (IQR 7.0–14.6);
• thrombosis: median days between tests 
12.6 (IQR 7.5–18.8); and 
• atrial fibrillation: median days between 
tests 13.2 (IQR 7.9–18.4). 
Those who were only self-testing had 
the longest time between tests (median 
days between tests 14.7, IQR 9.7–21.1) and 
those self-managing the shortest (median 
days between tests 8.3, IQR 6.0–13.5); those 
undertaking a mixture were situated in 
between (median days between tests 9.8, 
IQR 5.8–15.9).
Quality assurance
Nearly two-thirds (171/267, 64.0%) had 
performed an external calibration check 
of their device during the 12-month period. 
Of these, 50.8% compared their monitor 
with another monitor, 43.2% compared it 
with a venous sample, and 3.5% compared 
it with both; 2.3% were unknown. The 
majority (n = 117, 68.4%) had been advised 
to perform quality-assurance checks by 
their healthcare provider; the remainder 
used their initiative and coincided a self-
monitoring test with a clinic monitoring 
appointment. The number of quality-
assurance checks performed during the 
12 months ranged from 1 to 24 (median 2, 
IQR 1–4).
Time in therapeutic range
INR data was received from 273 
participants (92.2% of the 296 who started 
self-monitoring) and was analysed for 269 
(90.9%). Median %TTR was 78.5% (IQR 
64.9–88.5). Table 3 shows that the older 
age groups had the highest %TTR. There 
was little difference in %TTR between 
those new to self-monitoring (median 
76.1%, IQR 65.0–87.0) and those continuing 
to self-monitor (median 80.1%, IQR 64.8–
91.4). 
A total of 61 participants reported 
differing therapeutic ranges over the year. 
The breadth of INR target ranges started 
from as low as 0.4; the majority of cases 
(n = 243/296, 82.1%) had a range of 1 and 
the broadest range was 2. At 12 months, 
GPs were asked for their patient’s target 
range. These were compared with the 
target ranges reported by the participants 
at either the 12-month telephone interview 
or the last completed interview; for 80 
participants (80/255, 31.4%) target 
ranges did not match. In 27 instances the 
participant reported a narrower range and 
in 25 the GP reported a narrower range; 
in the remaining 28 cases the breadth 
was the same but the actual range was 
different.
The participants’ 12-month mean 
%TTR (mean 75.3%, standard deviation 
16.9) was higher than that achieved by the 
intervention groups in five21,23,25–27 of the 
seven 21–27 published RCTs.
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Table 3. Percentage of time spent in therapeutic range
  % TTR, 
Age, years n median (IQR) Range
<39 23 75.0 (64.8–83.1) 15.3–100.0
40–49 38 71.9 (58.9–86.0) 24.9–100.0
50–59  56 76.6 (62.4–85.8) 26.1–98.4
60–69  100 78.9 (62.1–90.4) 28.4–100.0
70–79  45 85.0 (73.4–90.6) 23.8–100.0
≥80  7 90.7 (77.3–95.9) 54.9–100.0
All ages 269 78.5 (64.9–88.5) 15.3–100.0
IQR = interquartile range. TTR = time in therapeutic range.
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Successful self-monitoring
The majority of participants who 
commenced self-monitoring were still 
doing so 12 months later (267/296, 90.2%). 
In addition, the majority of participants did 
not experience serious adverse events 
over the 12 months (6/296, 2.0%) either 
GP or self-reported. Therefore, the main 
measure of successful self-monitoring 
was taken as the percentage of time in 
therapeutic range (TTR). Those who 
achieved >80% (n=128/269, 47.5%) of their 
time during follow-up in therapeutic range 
were defined as successful. Table 4 shows 
the logistic regressions, including the fixed 
variables and the baseline characteristics, 
that significantly differed at univariate level 
between those achieving ≤80% TTR and 
those with >80% TTR over the 12-month 
study period.
Results show that an increased EQ-5D 
visual scale was significantly associated 
with >80% TTR (OR 1.017, 95% CI 
= 1.001 to 1.034) as well as the forced 
variables of age and condition requiring 
oral anticoagulation. As antiphospholipid 
syndrome causes increased variability in 
INR the analysis was repeated removing 
these participants (n = 24). This resulted 
in the target INR becoming significant 
rather than the condition requiring 
anticoagulation, with those conditions with 
the lowest target ranges resulting in higher 
%TTR. Again age and a higher EQ-5D visual 
score were associated with higher %TTR.
DISCUSSION
Summary
These results demonstrate that patients can 
successfully self-monitor their INR outside 
trial settings. Successful self-monitoring 
was defined as having >80% TTR; nearly 
one-half of participants met this criterion. 
Increased age, OAT for atrial fibrillation or 
thrombosis, and having a higher score on 
the EQ-5D visual scale were all associated 
with success. When the participants with 
antiphospholipid syndrome were removed 
from the model only increased age and 
EQ-5D visual scale and lower target INR 
range were associated with success.
Of concern is that less than one-half the 
participants had received in-person training 
(46%) and, when it was present, this lasted, 
on average, for <1 hour. Instead, individuals 
appeared to rely solely on the training 
information that came with their device 
when it was purchased. Anticoagulation 
services varied in the support offered to 
patients wishing to self-monitor. Some 
had established systems, including 
training schemes, in place. In other 
areas, particularly those in which local GP 
surgeries were commissioned to provide 
anticoagulation services for their patients, 
approval to self-monitor was done on a 
more ad hoc basis without any dedicated 
schemes set up. Moreover, only 15% of those 
new to self-monitoring who were adjusting 
their own dosage of anticoagulation therapy 
had received in-person training when they 
commenced self-monitoring. 
This cohort comprised well-educated, 
professional people, who successfully 
managed their self-monitoring with 
relatively little training; they also had 
a high level of knowledge about oral 
anticoagulation which was not related to 
training. Participants were aware of quality 
assurance and nearly two-thirds had 
performed an external calibration check of 
their device over the 12 months. In addition, 
they were similar to the general population 
in terms of anxiety and depression. A 
small number of participants could not 
commence self-monitoring or dropped out 
due to lack of healthcare provider support. 
Table 4. Logistic regression predicting those with >80% time in 
therapeutic range
 Odds ratio 95% CI P-value
All participants (n = 269)
Age, yearsa 1.024 1.000 to 1.048 0.052
Malea 1.320 0.753 to 2.312 0.332
Condition requiring oral anticoagulation therapya 
 Antiphospholipid syndrome 1.000 – 
 Atrial fibrillation 5.231 1.249 to 21.904 0.024 
 Mechanical heart valve 3.685 0.933 to 14.555 0.063 
 Thrombosis 4.684 1.209 to 18.149 0.025
Duration of self-monitoring, monthsa 1.004 0.998 to 1.010 0.225
Procedure during follow-upa 
 Major 1.000 – 
 None 2.181 0.907 to 5.242 0.081 
 Minor 0.885 0.270 to 2.889 0.840
Previous OAT complicationa 0.630 0.352 to 1.126 0.119
EQ-5D visual scale 1.017 1.001 to 1.034 0.032
Participants with antiphospholipid syndrome excluded (n = 245)
Age, yearsa 1.025 1.003 to 1.049 0.027
Malea 1.303 0.736 to 2.306 0.364
Duration of self-monitoring, monthsa 1.003 0.997 to 1.010 0.295
Procedure during follow-upa 
 Major 1.000 – 
 None 2.023 0.836 to 4.893 0.118 
 Minor 0.734 0.221 to 2.443 0.614
Previous OAT complicationa 0.752 0.412 to 1.374 0.354
EQ-5D visual scale 1.019 1.003 to 1.036 0.020
Target INR 0.480 0.246 to 0.939 0.032
aVariables the model was required to include. INR = international normalised ratio. OAT = oral anticoagulation 
therapy.
Strengths and limitations 
To the authors’ knowledge this is the 
first prospective cohort study of people 
self-monitoring their INR outside of trial 
conditions; the modified study design 
allowed for comparisons between those 
new to self-monitoring and those who had 
been self-monitoring for some time. 
A limitation of the study is that, due to 
the fact that self-monitoring INR devices 
are expensive (approximately £400 in the 
UK), the participants were those people 
who were well educated and able to afford 
the device. This is of concern as the results 
may, therefore, not be generalisable to the 
wider population and current provision may 
be widening inequalities in health care. 
Another potential limitation is the fact 
that the study, in part, relied on participants’ 
self-reported INR results. However, the 
accuracy of these have been confirmed 
in a small sample in which the reported 
results were compared to those stored in 
the memory of their monitor.
Comparison with existing literature
The majority of participants were still self-
monitoring at 12 months, with a level of 
control higher than that achieved by the 
majority of participants in other RCTs.21–
27 These results are consistent with the 
findings of a large retrospective study28 of 
patient self-testing, which showed a high 
level of control in males (76%TTR), females 
(71%TTR), and older patients (>74 years, 
>73% TTR). In addition, the low number of 
adverse events compares favourably with 
rates for those in the intervention arms of 
the RCTs (7.5%).3 
Implications for practice
This study reliably shows that participants 
can effectively self-monitor their own INR, 
but current provision is limited due to the 
initial costs of the device and the lack of 
healthcare provider support. 
Even with little training, people on OAT 
can successfully self-monitor and self-
manage their INR; however, the fact that 
one-third of the participants gave different 
target INR ranges from the ones provided 
by their GP at the end of this study suggests 
that closer monitoring by healthcare 
providers may be warranted. 
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Appendix 1. Baseline self-rated anxiety and depression of the CASM 
cohort members compared to population data using the Hospital 
Anxiety and Depression Scorea
 Male Female
 CASM (n = 162) Populationb CASM (n = 133) Populationb
HADS anxiety score, median (IQR) 4.0 5.0 5.0 6.0 
 (2.0–7.0) (3.0–8.0) (3.0–8.0) (4.0–9.0)
HADS depression score, median (IQR) 3.0 3.0 3.0 3.0 
 (1.0–5.0) (1.0–6.0) (1.0–6.0) (1.0–6.0)
IQR = interquartile range. aA score of 0–7 is regarded as being normal, ≥8 indicates the presence of anxiety or 
depression. Population data from: Crawford JR, Henry JD, Crombie C, Taylor EP. Normative data for the HADS 
from a large non-clinical sample. Br J Clin Psychol 2001; 40(Pt 4): 429–434.
